MovDisordV3, PascalFrancis, Corpus, bibRecord, 002974

Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine

Identifieur interne : 002974 ( PascalFrancis/Corpus ); précédent : 002973; suivant : 002975

Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine

Auteurs : Frithjof Tergau ; Stephan Wischer ; Christian Wolf ; Walter Paulus

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:01-0429245

Descripteurs français

Pascal (Inist)
- Impatience membre inférieur syndrome, α-Dihydroergocryptine, Agoniste, Récepteur dopaminergique D2, Chimiothérapie, Traitement, Homme, Etude préalable.

English descriptors

KwdEn :
- Agonist, Chemotherapy, D2 Dopamine receptor, Human, Previous study, Restless legs syndrome, Treatment, α-Dihydroergocryptine.

Abstract

An open pilot study with the dopamine agonist α-dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug-free interval of I week, the patients were treated with daily doses of 10 to 40 mg DHEC. As compared to baseline values, treatment led to a statistically significant reduction of subjective RLS symptoms. Overall complaints at night decreased significantly by 63.9 ± 38.1% as measured by a visual analogue scale. Detailed evaluation of sensory discomfort, motor restlessness, involuntary movements, as well as sleep quality also showed significant improvement. Side effects were mostly mild and affected mainly the gastrointestinal tract. Five patients needed domperidone for treatment of concomitant nausea. One patient stopped the study due to nausea. In conclusion, the results of this open study suggest a role for DHEC in the treatment of RLS.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine`
A11	`01`	`1`		`@1 TERGAU (Frithjof)`
A11	`02`	`1`		`@1 WISCHER (Stephan)`
A11	`03`	`1`		`@1 WOLF (Christian)`
A11	`04`	`1`		`@1 PAULUS (Walter)`
A14	`01`			`@1 Department of Clinical Neurophysiology, Georg-August University Göttingen @3 DEU @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Desitin Arzneimittel GmbH @2 Hamburg @3 DEU @Z 3 aut.`
A20				`@1 731-735`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000097121190210`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 19 ref.`
A47	`01`	`1`		`@0 01-0429245`
A60				`@1 P @3 EC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 An open pilot study with the dopamine agonist α-dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug-free interval of I week, the patients were treated with daily doses of 10 to 40 mg DHEC. As compared to baseline values, treatment led to a statistically significant reduction of subjective RLS symptoms. Overall complaints at night decreased significantly by 63.9 ± 38.1% as measured by a visual analogue scale. Detailed evaluation of sensory discomfort, motor restlessness, involuntary movements, as well as sleep quality also showed significant improvement. Side effects were mostly mild and affected mainly the gastrointestinal tract. Five patients needed domperidone for treatment of concomitant nausea. One patient stopped the study due to nausea. In conclusion, the results of this open study suggest a role for DHEC in the treatment of RLS.
C02	`01`	`X`		`@0 002B02B09A`
C02	`02`	`X`		`@0 002B17A01`
C03	`01`	`X`	`FRE`	`@0 Impatience membre inférieur syndrome @5 01`
C03	`01`	`X`	`ENG`	`@0 Restless legs syndrome @5 01`
C03	`01`	`X`	`SPA`	`@0 Acroparestesia nocturna @5 01`
C03	`02`	`X`	`FRE`	`@0 α-Dihydroergocryptine @2 NK @2 FR @5 04 @6 «α»-Dihydroergocryptine`
C03	`02`	`X`	`ENG`	`@0 α-Dihydroergocryptine @2 NK @2 FR @5 04 @6 «α»-Dihydroergocryptine`
C03	`02`	`X`	`SPA`	`@0 α-Dihidroergocriptina @2 NK @2 FR @5 04 @6 «α»-Dihidroergocriptina`
C03	`03`	`X`	`FRE`	`@0 Agoniste @5 05`
C03	`03`	`X`	`ENG`	`@0 Agonist @5 05`
C03	`03`	`X`	`SPA`	`@0 Agonista @5 05`
C03	`04`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 06`
C03	`04`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 06 @6 «D2» Dopamine receptor`
C03	`04`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 06`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`07`	`X`	`FRE`	`@0 Homme @5 20`
C03	`07`	`X`	`ENG`	`@0 Human @5 20`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`08`	`X`	`FRE`	`@0 Etude préalable @5 23`
C03	`08`	`X`	`ENG`	`@0 Previous study @5 23`
C03	`08`	`X`	`SPA`	`@0 Estudio previo @5 23`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Trouble neurologique @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurological disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Trastorno neurológico @5 38`
C07	`03`	`X`	`FRE`	`@0 Trouble sensibilité @5 39`
C07	`03`	`X`	`ENG`	`@0 Sensitivity disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Trastorno sensibilidad @5 39`
N21				`@1 302`

Format Inist (serveur)

NO :	PASCAL 01-0429245 INIST
ET :	Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine
AU :	TERGAU (Frithjof); WISCHER (Stephan); WOLF (Christian); PAULUS (Walter)
AF :	Department of Clinical Neurophysiology, Georg-August University Göttingen/Allemagne (1 aut., 2 aut., 4 aut.); Desitin Arzneimittel GmbH/Hamburg/Allemagne (3 aut.)
DT :	Publication en série; Etude de cas, cas et faits cliniques; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 4; Pp. 731-735; Bibl. 19 ref.
LA :	Anglais
EA :	An open pilot study with the dopamine agonist α-dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug-free interval of I week, the patients were treated with daily doses of 10 to 40 mg DHEC. As compared to baseline values, treatment led to a statistically significant reduction of subjective RLS symptoms. Overall complaints at night decreased significantly by 63.9 ± 38.1% as measured by a visual analogue scale. Detailed evaluation of sensory discomfort, motor restlessness, involuntary movements, as well as sleep quality also showed significant improvement. Side effects were mostly mild and affected mainly the gastrointestinal tract. Five patients needed domperidone for treatment of concomitant nausea. One patient stopped the study due to nausea. In conclusion, the results of this open study suggest a role for DHEC in the treatment of RLS.
CC :	002B02B09A; 002B17A01
FD :	Impatience membre inférieur syndrome; α-Dihydroergocryptine; Agoniste; Récepteur dopaminergique D2; Chimiothérapie; Traitement; Homme; Etude préalable
FG :	Système nerveux pathologie; Trouble neurologique; Trouble sensibilité
ED :	Restless legs syndrome; α-Dihydroergocryptine; Agonist; D2 Dopamine receptor; Chemotherapy; Treatment; Human; Previous study
EG :	Nervous system diseases; Neurological disorder; Sensitivity disorder
SD :	Acroparestesia nocturna; α-Dihidroergocriptina; Agonista; Receptor dopaminérgico D2; Quimioterapia; Tratamiento; Hombre; Estudio previo
LO :	INIST-20953.354000097121190210
ID :	01-0429245

Links to Exploration step

Pascal:01-0429245

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine</title>
<author><name sortKey="Tergau, Frithjof" sort="Tergau, Frithjof" uniqKey="Tergau F" first="Frithjof" last="Tergau">Frithjof Tergau</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurophysiology, Georg-August University Göttingen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wischer, Stephan" sort="Wischer, Stephan" uniqKey="Wischer S" first="Stephan" last="Wischer">Stephan Wischer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurophysiology, Georg-August University Göttingen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wolf, Christian" sort="Wolf, Christian" uniqKey="Wolf C" first="Christian" last="Wolf">Christian Wolf</name>
<affiliation><inist:fA14 i1="02"><s1>Desitin Arzneimittel GmbH</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Paulus, Walter" sort="Paulus, Walter" uniqKey="Paulus W" first="Walter" last="Paulus">Walter Paulus</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurophysiology, Georg-August University Göttingen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0429245</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0429245 INIST</idno>
<idno type="RBID">Pascal:01-0429245</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002974</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine</title>
<author><name sortKey="Tergau, Frithjof" sort="Tergau, Frithjof" uniqKey="Tergau F" first="Frithjof" last="Tergau">Frithjof Tergau</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurophysiology, Georg-August University Göttingen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wischer, Stephan" sort="Wischer, Stephan" uniqKey="Wischer S" first="Stephan" last="Wischer">Stephan Wischer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurophysiology, Georg-August University Göttingen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wolf, Christian" sort="Wolf, Christian" uniqKey="Wolf C" first="Christian" last="Wolf">Christian Wolf</name>
<affiliation><inist:fA14 i1="02"><s1>Desitin Arzneimittel GmbH</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Paulus, Walter" sort="Paulus, Walter" uniqKey="Paulus W" first="Walter" last="Paulus">Walter Paulus</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurophysiology, Georg-August University Göttingen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Chemotherapy</term>
<term>D2 Dopamine receptor</term>
<term>Human</term>
<term>Previous study</term>
<term>Restless legs syndrome</term>
<term>Treatment</term>
<term>α-Dihydroergocryptine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Impatience membre inférieur syndrome</term>
<term>α-Dihydroergocryptine</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude préalable</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An open pilot study with the dopamine agonist α-dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug-free interval of I week, the patients were treated with daily doses of 10 to 40 mg DHEC. As compared to baseline values, treatment led to a statistically significant reduction of subjective RLS symptoms. Overall complaints at night decreased significantly by 63.9 ± 38.1% as measured by a visual analogue scale. Detailed evaluation of sensory discomfort, motor restlessness, involuntary movements, as well as sleep quality also showed significant improvement. Side effects were mostly mild and affected mainly the gastrointestinal tract. Five patients needed domperidone for treatment of concomitant nausea. One patient stopped the study due to nausea. In conclusion, the results of this open study suggest a role for DHEC in the treatment of RLS.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TERGAU (Frithjof)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WISCHER (Stephan)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>WOLF (Christian)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PAULUS (Walter)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Clinical Neurophysiology, Georg-August University Göttingen</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Desitin Arzneimittel GmbH</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>731-735</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000097121190210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0429245</s0>
</fA47>
<fA60><s1>P</s1>
<s3>EC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>An open pilot study with the dopamine agonist α-dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug-free interval of I week, the patients were treated with daily doses of 10 to 40 mg DHEC. As compared to baseline values, treatment led to a statistically significant reduction of subjective RLS symptoms. Overall complaints at night decreased significantly by 63.9 ± 38.1% as measured by a visual analogue scale. Detailed evaluation of sensory discomfort, motor restlessness, involuntary movements, as well as sleep quality also showed significant improvement. Side effects were mostly mild and affected mainly the gastrointestinal tract. Five patients needed domperidone for treatment of concomitant nausea. One patient stopped the study due to nausea. In conclusion, the results of this open study suggest a role for DHEC in the treatment of RLS.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B09A</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Impatience membre inférieur syndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Restless legs syndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Acroparestesia nocturna</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>α-Dihydroergocryptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
<s6>«α»-Dihydroergocryptine</s6>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>α-Dihydroergocryptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
<s6>«α»-Dihydroergocryptine</s6>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>α-Dihidroergocriptina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
<s6>«α»-Dihidroergocriptina</s6>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Agonist</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Agonista</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>06</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude préalable</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Previous study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio previo</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble sensibilité</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Sensitivity disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno sensibilidad</s0>
<s5>39</s5>
</fC07>
<fN21><s1>302</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 01-0429245 INIST</NO>
<ET>Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine</ET>
<AU>TERGAU (Frithjof); WISCHER (Stephan); WOLF (Christian); PAULUS (Walter)</AU>
<AF>Department of Clinical Neurophysiology, Georg-August University Göttingen/Allemagne (1 aut., 2 aut., 4 aut.); Desitin Arzneimittel GmbH/Hamburg/Allemagne (3 aut.)</AF>
<DT>Publication en série; Etude de cas, cas et faits cliniques; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 4; Pp. 731-735; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>An open pilot study with the dopamine agonist α-dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug-free interval of I week, the patients were treated with daily doses of 10 to 40 mg DHEC. As compared to baseline values, treatment led to a statistically significant reduction of subjective RLS symptoms. Overall complaints at night decreased significantly by 63.9 ± 38.1% as measured by a visual analogue scale. Detailed evaluation of sensory discomfort, motor restlessness, involuntary movements, as well as sleep quality also showed significant improvement. Side effects were mostly mild and affected mainly the gastrointestinal tract. Five patients needed domperidone for treatment of concomitant nausea. One patient stopped the study due to nausea. In conclusion, the results of this open study suggest a role for DHEC in the treatment of RLS.</EA>
<CC>002B02B09A; 002B17A01</CC>
<FD>Impatience membre inférieur syndrome; α-Dihydroergocryptine; Agoniste; Récepteur dopaminergique D2; Chimiothérapie; Traitement; Homme; Etude préalable</FD>
<FG>Système nerveux pathologie; Trouble neurologique; Trouble sensibilité</FG>
<ED>Restless legs syndrome; α-Dihydroergocryptine; Agonist; D2 Dopamine receptor; Chemotherapy; Treatment; Human; Previous study</ED>
<EG>Nervous system diseases; Neurological disorder; Sensitivity disorder</EG>
<SD>Acroparestesia nocturna; α-Dihidroergocriptina; Agonista; Receptor dopaminérgico D2; Quimioterapia; Tratamiento; Hombre; Estudio previo</SD>
<LO>INIST-20953.354000097121190210</LO>
<ID>01-0429245</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002974 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002974 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:01-0429245
   |texte=   Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine

Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri